MOCS3抗体—艾普蒂

+ +

•  

   

     APCS Antibody (C-term) (Cat. #P30828) western blot analysis in K562 cell line lysates (35ug/lane).This demonstrates the APCS antibody detected the APCS protein (arrow).    

  
  

•  

   

     APCS antibody (C-term) (Cat. #P30828) immunohistochemistry analysis in formalin fixed and paraffin embedded human hepatocarcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining.  This data demonstrates the use of the APCS antibody (C-term) for immunohistochemistry.  Clinical relevance has not been evaluated.    

  
  

The MOCS3 antibody is designed to detect MOCS3 (Molybdenum Cofactor Synthesis 3), a critical enzyme involved in the biosynthesis of the molybdenum cofactor (MoCo), an essential component for the activity of molybdoenzymes such as sulfite oxidase and xanthine dehydrogenase. MOCS3 functions as a dual-domain protein, combining a N-terminal domain with adenylation activity and a C-terminal rhodanese-like domain responsible for sulfur transfer. It plays a dual role in MoCo synthesis: first, in the conversion of precursor Z to molybdopterin by adenylating MOCS2A and transferring sulfur to MOCS2B, and second, in the thiolation of tRNA, linking it to cellular sulfur metabolism.

Mutations in MOCS3 are associated with MoCo deficiency, a rare autosomal recessive disorder characterized by severe neurological symptoms and early lethality. The antibody is widely used in research to study MoCo biosynthesis pathways, sulfur transfer mechanisms, and the protein's role in redox homeostasis. It aids in detecting MOCS3 expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence, providing insights into its tissue-specific distribution and subcellular localization (primarily cytoplasmic and nuclear). Studies leveraging this antibody have also explored its potential involvement in cancer progression and neurodegenerative diseases, given its regulatory role in cellular detoxification and oxidative stress responses. Commercial MOCS3 antibodies are typically validated for specificity using knockout cell lines or siRNA-based silencing to ensure reliable experimental outcomes.